An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on November 9, 2023. The company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business update and review financial results. Investors can access the webcast on the company's website or join the conference call using the provided dial-in numbers.
Positive
None.
Negative
None.
Company to host conference call and webcast on November 9, 2023, at 1:30 p.m. GMT / 8:30 a.m. EST
OXFORD, England--(BUSINESS WIRE)--
Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business update and review financial results.
A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.
About Exscientia
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
When will Exscientia plc report its financial results for the third quarter of 2023?
Exscientia plc will report its financial results for the third quarter ended September 30, 2023, on November 9, 2023.
What time will the conference call and webcast take place?
The conference call and webcast will take place at 1:30 p.m. GMT / 8:30 a.m. EST.
How can investors access the webcast?
Investors can access the webcast by visiting the 'Investors and Media' section of the Exscientia website at investors.exscientia.ai.
How can investors join the conference call?
Investors can join the conference call by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895.
Will there be a replay of the conference call available?
Yes, a replay of the conference call will be available for 90 days under 'Events and Presentations' in the 'Investors and Media' section of the Exscientia website.
at the forefront of small molecule drug discovery we are the first company to automate drug design, surpassing conventional human endeavour. our ai driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. with better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, adme and other key criteria. from this, a selection of the best, information-rich compounds are selected for synthesis and assay. with new experimental data generated, the results are integrated and the next design cycle initiated. rapid design-make-test cycles ensure unparalleled progress towards desired project goals. exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
